Recent evidence suggests that purinergic system dysfunction may play a role in the pathophysiology and therapeutics of bipolar disorder (BPD). Uric acid is a key nitrogenous end product of purine metabolism. In addition to being a potential marker of treatment response, high levels of uric acid may represent a state marker during mania. In this study, we assessed the presence of purinergic dysfunction in 20 treatmentnaïve first episode patients with BPD who were experiencing a manic episode. Patients were matched with 24 healthy controls. We found that acutely manic patients had significantly higher levels of plasma uric acid (4.85 ± 1.60 mg/dL) compared to healthy controls (2.96 ± 0.63 mg/dL, p b 0.001; F = 28.1). No association between uric acid levels with severity of manic symptoms was observed. These results support the role of purinergic system dysfunction in BPD early in the course of illness, and suggest that this phenomenon is not the result of chronicity or medication exposure. Overall, our findings suggest a novel mechanism in the pathophysiology of BPD.
Introduction
Improved understanding of the pathophysiological basis of bipolar disorder (BPD) is critical for the development of improved therapeutics needed to treat this devastating illness.
Recent evidences from genetic and clinical studies suggest that purinergic system dysfunction may play an important role in the pathophysiology and therapeutics of BPD (McQuillin et al., 2009; Zarate and Manji, 2008; Machado-Vieira et al., 2008) . A recent randomized, placebo-controlled trial showed that the purinergic modulator allopurinol, a xanthine oxidase inhibitor, was effective in treating acute mania when used adjunctively with lithium (MachadoVieira et al., 2008) . The same study also found that change in Young Mania Rating Scale (YMRS) (Young et al., 1978) scores from baseline to endpoint was positively correlated with change in plasma uric acid levels. Furthermore, remitters were significantly more likely to have lower uric acid plasma levels than non-remitters. This suggests that uric acid levels might serve not only as a surrogate marker of clinical efficacy, but also as a state marker during manic episodes.
Previous studies reported that plasma uric acid levels were higher only during the manic phase of BPD but not during the depressive or euthymic phases (De Berardis et al., 2008) . However, several factors could affect interpretation of those findings, including the use of concomitant medications, cycling, and chronicity of the illness. Examining plasma uric acid levels early in the course of illness in patients experiencing their first episode of mania, and prior to first medication exposure, might help disentangle the effects of some of these potential confounders.
In the present investigation, plasma uric acid levels were evaluated in first episode, drug-naïve, manic patients. We hypothesized that patients with BPD would have higher uric acid levels than age-and gender-matched healthy controls.
Methods

Subjects
Twenty drug-naïve inpatients meeting criteria for a first manic episode of BPD were enrolled in this study (4 men, 16 women; mean age = 24.9 ± 2.8 years). Diagnoses were established by a psychiatrist using the Structured Clinical Interview for DSM-IV (SCID) (First et al., 2002a,b) . Subjects with other Axis I disorders and/or severe or unstable medical illnesses were excluded from the study. Patients with gout, chronic inflammatory disease, or other diseases associated Abbreviations: BPD, bipolar disorder; CNS, central nervous system; YMRS, Young Mania Rating Scale.
